EIDX Eidos Therapeutics Inc.

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Latest News

1. 26 February 2020 Eidos Therapeutics Reports Fourth Quarter and Year-End 2019 Financial Results and Business Update

   SAN FRANCISCO, Feb. 26, 2020 (GLOBE NEWSWIRE) -- Eidos Therapeutics, Inc. (Eidos) (NASDAQ:EIDX), today reported its financial results for the fourth quarter and full year ended December 31, 2019 and provided an update

2. 21 February 2020 BridgeBio Pharma And Eidos Therapeutics To Present At Upcoming Investor Conferences

   PALO ALTO, Calif., Feb. 21, 2020 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (NASDAQ:BBIO), together with affiliate company Eidos Therapeutics (NASDAQ:EIDX) announced today that they are presenting at two upcoming

3. 16 November 2019 BridgeBio and Eidos Present Data from Phase 2 Open Label Extension Suggesting Long-term Tolerability of AG10 and Stabilization of Transthyretin Amyloid Cardiomyopathy Disease Measures

   AG10 was Well Tolerated with Median 65 Weeks Follow-up since Phase 2 Initiation Rates of All-Cause Mortality (Including Either Death or Cardiac Transplantation, 8.5%) and Cardiovascular Hospitalization (25.5%)

4. 31 October 2019 Eidos Therapeutics Reports Third Quarter 2019 Financial Results and Business Update

   SAN FRANCISCO, Oct. 31, 2019 (GLOBE NEWSWIRE) -- Eidos Therapeutics, Inc. (Eidos) (NASDAQ:EIDX), a subsidiary of BridgeBio Pharma, Inc. (BridgeBio) (NASDAQ:BBIO), today reported its financial results for the third

5. 14 October 2019 BridgeBio Pharma Terminates Merger Process With Its Subsidiary Eidos Therapeutics

   Agreement Not Reached Between BridgeBio Pharma and Special Committee of Eidos Therapeutics Independent Directors; BridgeBio No Longer Pursuing Acquisition BridgeBio Pharma, Inc. (NASDAQ:BBIO), a clinical-stage

6. 30 September 2019 Eidos Therapeutics to Present Interim Analysis of the Ongoing Phase 2 Open-Label Extension Study of AG10 in Patients with TTR Amyloid Cardiomyopathy at the AHA 2019 Scientific Sessions in a Late-Breaking Featured Science Oral Presentation

   SAN FRANCISCO, Sept. 30, 2019 (GLOBE NEWSWIRE) -- Eidos Therapeutics, Inc. (Eidos) (NASDAQ:EIDX), a clinical stage biopharmaceutical company focused on addressing the large and growing unmet need in transthyretin

7. 19 September 2019 Eidos Therapeutics to Present at the 2019 Cantor Global Healthcare Conference

   SAN FRANCISCO, Sept. 19, 2019 (GLOBE NEWSWIRE) -- Eidos Therapeutics, Inc. (Eidos) (NASDAQ:EIDX) today announced that management will present at the 2019 Cantor Global Healthcare Conference on Thursday, October 3rd at

8. 12 September 2019 Eidos Therapeutics Special Committee Rejects Proposal from BridgeBio Pharma to Acquire Shares

   Advises Stockholders Take No Action at this Time Eidos Therapeutics, Inc. (NASDAQ:EIDX) ("Eidos") announced today that the Special Committee of its Board of Directors (the "Special Committee") unanimously rejected the

9. 03 September 2019 Kaskela Law LLC Announces Shareholder Investigation of Eidos Therapeutics, Inc. and Encourages Investors to Contact the Firm – EIDX

   PHILADELPHIA, Sept. 03, 2019 (GLOBE NEWSWIRE) -- Kaskela Law LLC is investigating Eidos Therapeutics, Inc. ("Eidos") (NASDAQ:EIDX) on behalf of the company's shareholders.  The investigation seeks to determine whether